For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 1,644 | |||
| General and administrative expenses | 1,820 | |||
| Intangible asset and goodwill impairment expenses | 9,684 | |||
| Operating loss | -13,148 | |||
| Financial expense (income), net | 57 | |||
| Loss before tax expenses | -13,091 | |||
| Tax expenses | 358 | |||
| Net loss and comprehensive loss | -13,449 | |||
| Basic EPS | 0.22 | |||
| Diluted EPS | 0.22 | |||
| Basic Average Shares | 60,729,100 | |||
| Diluted Average Shares | 60,729,100 | |||
Revium Rx. (RVRC)
Revium Rx. (RVRC)